Connect
MJA
MJA

Endocrine Society of Australia position statement on male hypogonadism (part 2): treatment and therapeutic considerations

Bu B Yeap, Mathis Grossmann, Robert I McLachlan, David J Handelsman, Gary A Wittert, Ann J Conway, Bronwyn GA Stuckey, Douglas W Lording, Carolyn A Allan, Jeffrey D Zajac and Henry G Burger
Med J Aust 2016; 205 (5): 228-231. || doi: 10.5694/mja16.00448

Summary

Introduction: Part 1 of this position statement dealt with the assessment of male hypogonadism, including the indications for testosterone therapy. This article, Part 2, focuses on treatment and therapeutic considerations for male hypogonadism and identifies key questions for future research.

Main recommendations: Key points and recommendations are:

  • Excess cardiovascular events have been reported in some but not all studies of older men without pathological hypogonadism who were given testosterone treatment. Additional studies are needed to clarify whether testosterone therapy influences cardiovascular risk.
  • Testosterone is the native hormone that should be replaced in men being treated for pathological hypogonadism. Convenient and cost-effective treatment modalities include depot intramuscular injection and transdermal administration (gel, cream or liquid formulations).
  • Monitoring of testosterone therapy is recommended for efficacy and safety, focusing on ameliorating symptoms, restoring virilisation, avoiding polycythaemia and maintaining or improving bone mineral density.
  • Treatment aims to relieve an individual’s symptoms and signs of androgen deficiency by administering standard doses and maintaining circulating testosterone levels within the reference interval for eugonadal men.
  • Evaluation for cardiovascular disease and prostate cancer risks should be undertaken as appropriate for eugonadal men of similar age. Nevertheless, when there is a reasonable possibility of substantive pre-existing prostate disease, digital rectal examination and prostate-specific antigen testing should be performed before commencing testosterone treatment.

Changes in management as result of the position statement: Treatment aims to relieve symptoms and signs of androgen deficiency, using convenient and effective formulations of testosterone. Therapy should be monitored for efficacy and safety.

Please login with your free MJA account to view this article in full

  • Bu B Yeap1
  • Mathis Grossmann2
  • Robert I McLachlan3
  • David J Handelsman4
  • Gary A Wittert5,6
  • Ann J Conway4
  • Bronwyn GA Stuckey1,7
  • Douglas W Lording8
  • Carolyn A Allan3
  • Jeffrey D Zajac2
  • Henry G Burger3

  • 1 School of Medicine and Pharmacology, University of Western Australia, Perth, WA
  • 2 Department of Medicine, Austin Health, University of Melbourne, Melbourne, VIC
  • 3 Hudson Institute of Medical Research, Melbourne, VIC
  • 4 ANZAC Research Institute, University of Sydney, Sydney, NSW
  • 5 Discipline of Medicine, University of Adelaide, Adelaide, SA
  • 6 Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, SA
  • 7 Keogh Institute for Medical Research, Sir Charles Gairdner Hospital, Perth, WA
  • 8 Endocrinology, Cabrini Hospital, Melbourne, VIC

Correspondence: bu.yeap@uwa.edu.au

Competing interests:

Author disclosures are listed in the Appendix.

  • 1. Conway AJ, Handelsman DJ, Lording DW, et al. Use, misuse and abuse of androgens. The Endocrine Society of Australia consensus guidelines for androgen prescribing. Med J Aust 2000; 172: 220-224. Erratum in: Med J Aust 2000; 172: 334. <MJA full text>
  • 2. Australian Government Department of Health. Pharmaceutical Benefits Scheme. Testosterone undecanoate. http://www.pbs.gov.au/medicine/item/10205D (accessed Nov 2015).
  • 3. Yeap BB, Grossmann M, McLachlan RI, et al. Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy. Med J Aust 2016; 205: 173-178. <MJA full text>
  • 4. Yeap BB. Testosterone and cardiovascular disease risk. Curr Opin Endocrinol Diabetes Obes 2015; 22: 193-202.
  • 5. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med 2010; 363: 109-122.
  • 6. Srinivas-Shankar U, Roberts SA, Connolly MJ, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010; 95: 639-650.
  • 7. Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. N Engl J Med 2016; 374: 611-624.
  • 8. Basaria S, Harman SM, Travison TG, et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial. JAMA 2015; 314: 570-581.
  • 9. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med 2013; 11: 108.
  • 10. Corona G, Maseroli E, Rastrelli G, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf 2014; 13: 1327-1351.
  • 11. Borst SE, Shuster JJ, Zou B, et al. Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis. BMC Medicine 2014; 12: 211.
  • 12. Sharma R, Oni OA, Gupta K, et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J 2015; 36: 2706-2715.
  • 13. US Food and Drug Administration. FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. 3 Mar 2015. http://www.fda.gov/Drugs/DrugSafety/ucm436259.htm (accessed Mar 2015).
  • 14. US Food and Drug Administration. Summary minutes of the Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. September 17, 2014. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM418144.pdf (accessed Nov 2015).
  • 15. Lakshman KM, Kaplan B, Travison TG, et al. The effects of injected testosterone dose and age on the conversion of testosterone to estradiol and dihydrotestosterone in young and older men. J Clin Endocrinol Metab 2010; 95: 3955-3964.
  • 16. Finkelstein JS, Lee H, Burnett-Bowie SA, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med 2013; 369: 1011-1022.
  • 17. Sartorius GA, Ly LP, Handelsman DJ. Male sexual function can be maintained without aromatisation: randomized placebo-controlled trial of dihydrotestosterone (DHT) in healthy, older men for 24 months. J Sex Med 2014; 11: 2562-2570.
  • 18. Kelleher S, Conway AJ, Handelsman DJ. Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab 2004; 89: 3813-3817.
  • 19. Aminorroaya A, Kelleher S, Conway AJ, et al. Adequacy of androgen replacement influences bone density response to testosterone in androgen-deficient men. Eur J Endocrinol 2005; 152: 881-886.
  • 20. Swerdlow AJ, Schoemaker MJ, Higgins CD, et al. Cancer incidence and mortality in men with Klinefelter syndrome: a cohort study. J Natl Cancer Inst 2005; 97: 1204-1210.
  • 21. Cui Y, Zong H, Yan H, Zhang Y. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2014; 17: 132-143.
  • 22. Baillargeon J, Kuo Y-F, Fang X, Shahinian VB. Long-term exposure to testosterone therapy and the risk of high grade prostate cancer. J Urol 2015; 194: 1612-1616.
  • 23. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev 2013; (1): CD004720.
  • 24. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95: 2536-2559.
  • 25. Grunstein RR, Handelsman DJ, Lawrence SJ, et al. Neuroendocrine dysfunction in sleep apnoea: reversal by continuous positive airways pressure therapy. J Clin Endocrinol Metab 1989; 68: 352-358.
  • 26. Knapp A, Myhill PC, Davis WA, et al. Effect of continuous positive airway pressure therapy on sexual function and serum testosterone in males with type 2 diabetes and obstructive sleep apnoea. Clin Endocrinol (Oxf) 2014; 81: 254-258.
  • 27. Zhang XB, Jiang XT, Du YP, et al. Efficacy of continuous positive airway pressure on testosterone in men with obstructive sleep apnea: a meta-analysis. PLoS One 2014; 9: e115033.
  • 28. Killick R, Wang D, Hoyos CM, et al. The effects of testosterone on ventilatory responses in men with obstructive sleep apnea: a randomised, placebo-controlled trial. J Sleep Res 2013; 22: 331-336.
  • 29. Middleton T, Turner L, Fennell C, et al. Complications of injectable testosterone undecanoate in routine clinical practice. Eur J Endocrinol 2015; 172: 511-517.
  • 30. Sartorius G, Fennell C, Spasevska S, et al. Factors influencing time course of pain after depot oil intramuscular injection of testosterone undecanoate. Asian J Androl 2010; 12: 227-233.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.